Manchester Breast Centre (MBC) External Seminar Series, sponsored by Breast Cancer Now
Wednesday 12th February 2025, 3:00pm – 4:00pm
Professor Andrew Tutt
Institute of Cancer Research and Kings College London
Title: “Targeting HR deficient breast cancer: Extending PARPi indications and informing therapy development after resistance”
Live seminar at: OCRB Lecture Theatre, Oglesby Cancer Research Building, 555 Wilmslow Rd, Manchester M20 4GJ
If you would like to arrange a 1:1 meeting with Andrew during the day, please contact rebecca.murray@manchester.ac.uk
Professor Andrew Tutt MB ChB PhD FMedSci
Andrew is Professor of Breast Oncology, Head of the Division of Breast Cancer Research and Director of the Breast Cancer Now Toby Robins Research Centre, at the Institute of Cancer Research in London (ICR) and Breast Cancer Now Research Unit at King’s College London (KCL) where he is also a Professor of Clinical Oncology.
He is a practicing Consultant Clinical Oncologist as a member of the multidisciplinary Breast Units at Guy’s and St Thomas’ and Royal Marsden NHS Foundation Trusts. In his clinical role Andrew serves on the St Gallen Early Breast Cancer International Consensus Panel and the ESMO Breast Cancer Guidelines Group. He is a member of the Oxford Early Breast Cancer Trialists Cooperative Group (EBCTCG) Steering Committee, the Breast Cancer Research Foundation Scientific Advisory Board and is Chair of Cancer Research UK’s Clinical Research Committee.
In his own research he leads a joint translational science laboratory across the ICR and KCL with his cancer biology colleague Professor Christopher Lord, identifying and validating therapy targets, biomarkers and resistance mechanisms in these cancers. In his clinical trial work he focuses on cancers associated with functional deficiencies in DNA repair including BRCA1, BRCA2 and PALB2 and triple negative breast cancers.
In 2015 he received the Addarii Award from the University of Bologna for his work in the field of BRCA1 and BRCA2 associated breast and ovarian cancer. Andrew has since been elected to the Fellowship of the Academy of Medical Science and the European Academy of Cancer Sciences. He was awarded the ESMO Breast Cancer Award in 2021 and the Robert Sutherland Award for Excellence in Translational Research in 2024. Andrew is a passionate and committed team scientist and is hugely proud to have been part of the ICR and Royal Marsden Hospital Team awarded the AACR Team Science Award in 2022 and the ICR Breast Cancer Team awarded a Queen’s Anniversary Prize in 2024.
